NeuroMetrix (NURO) Reports Q2 Loss of $0.48/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Marvell shares jump after giving Google warrants amid custom chip deal
NeuroMetrix Reports Q2 2015 Financial Results and Highlights
July 22, 2015 7:00 AM EDTQuell Commercial Launch Milestone Achieved; Strong Early Shipments
WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (the Company) (Nasdaq: NURO), today reported financial and business highlights for the quarter ended June 30, 2015.
The Company operates in two primary markets - wearable therapeutic technology and point-of-care tests. Its newest product is Quell, an over-the-counter wearable pain relief device that utilizes proprietary non-invasive neurostimulation technology to provide relief from chronic pain. The device is designed for users with conditions such as diabetic nerve pain, low back and leg pain, fibromyalgia and pain associated with... More
